Researcher.Life Logo

The Lancet Microbe : Impact Factor & More

eISSN: 2666-5247pISSN: 2666-5247
JournalOpen Access

Key Metrics

CiteScore
18.4
Scite Index
0.89 5-Year SI
SNIP
6.5
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on The Lancet Microbe

The Lancet Microbe Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher ELSEVIER
Language English
Frequency Monthly
Article Processing ChargesUSD 6300
Publication Time6
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year2020
Publisher URLVisit website
Website URLVisit website
Publication Details
Other chargesVisit website
PlagiarismVisit website
Publication Time 6
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
License typeCC BY, CC BY-NC-ND
OA statementVisit website
View less

Planning to publish in The Lancet Microbe ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in The Lancet Microbe

Emergence of carbapenemase-producing Escherichia coli in acute care hospitals in 32 European countries (the CCRE survey): a prospective, multicentre, cross-sectional, epidemiological, microbiological, and genomic surveillance study.
  • 13 Apr 2027
  • The Lancet. Microbe
Persistent spread of carbapenemase-producing Klebsiella pneumoniae in acute care hospitals in 36 European countries (the CCRE survey): a prospective, multicentre, cross-sectional, epidemiological, microbiological, and genomic surveillance study.
  • 13 Apr 2027
  • The Lancet. Microbe
Nirmatrelvir-ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022-23: virological and immunological results of an open-label randomised trial (PANORAMIC).
  • 23 Mar 2027
  • The Lancet. Microbe
Diagnosis and treatment of female genital schistosomiasis.
  • 12 Jan 2027
  • The Lancet. Microbe
Female genital schistosomiasis, including zoonotic and hybrid schistosomes, and other cervicovaginal co-infections.
  • 13 May 2026
  • The Lancet. Microbe
Antimicrobial resistance in bacterial pathogens causing community-acquired and hospital-acquired lower respiratory tract infections (2010-24): a systematic review and meta-analysis.
  • 11 May 2026
  • The Lancet. Microbe
Emergence of carbapenemase-producing Escherichia coli in acute care hospitals in 32 European countries (the CCRE survey): a prospective, multicentre, cross-sectional, epidemiological, microbiological, and genomic surveillance study.
  • 13 Apr 2027
  • The Lancet. Microbe
Persistent spread of carbapenemase-producing Klebsiella pneumoniae in acute care hospitals in 36 European countries (the CCRE survey): a prospective, multicentre, cross-sectional, epidemiological, microbiological, and genomic surveillance study.
  • 13 Apr 2027
  • The Lancet. Microbe
Nirmatrelvir-ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022-23: virological and immunological results of an open-label randomised trial (PANORAMIC).
  • 23 Mar 2027
  • The Lancet. Microbe
Diagnosis and treatment of female genital schistosomiasis.
  • 12 Jan 2027
  • The Lancet. Microbe
Female genital schistosomiasis, including zoonotic and hybrid schistosomes, and other cervicovaginal co-infections.
  • 13 May 2026
  • The Lancet. Microbe
Antimicrobial resistance in bacterial pathogens causing community-acquired and hospital-acquired lower respiratory tract infections (2010-24): a systematic review and meta-analysis.
  • 11 May 2026
  • The Lancet. Microbe

FAQs on The Lancet Microbe